EP1115733A4 - SEQUENCE CHARACTERISTICS OF THE HYPOXIA-REGULATED GENE TRANSCRIPTION - Google Patents

SEQUENCE CHARACTERISTICS OF THE HYPOXIA-REGULATED GENE TRANSCRIPTION

Info

Publication number
EP1115733A4
EP1115733A4 EP99945523A EP99945523A EP1115733A4 EP 1115733 A4 EP1115733 A4 EP 1115733A4 EP 99945523 A EP99945523 A EP 99945523A EP 99945523 A EP99945523 A EP 99945523A EP 1115733 A4 EP1115733 A4 EP 1115733A4
Authority
EP
European Patent Office
Prior art keywords
hypoxia
gene transcription
regulated gene
sequences characteristic
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99945523A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1115733A1 (en
Inventor
Paz Einat
Rami Skaliter
Elena Feinstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quark Pharmaceuticals Inc
Original Assignee
Quark Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Biotech Inc filed Critical Quark Biotech Inc
Publication of EP1115733A1 publication Critical patent/EP1115733A1/en
Publication of EP1115733A4 publication Critical patent/EP1115733A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP99945523A 1998-08-27 1999-08-27 SEQUENCE CHARACTERISTICS OF THE HYPOXIA-REGULATED GENE TRANSCRIPTION Withdrawn EP1115733A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9815898P 1998-08-27 1998-08-27
US98158P 1998-08-27
US13268499P 1999-05-05 1999-05-05
US132684P 1999-05-05
PCT/US1999/020394 WO2000012525A1 (en) 1998-08-27 1999-08-27 Sequences characteristic of hypoxia-regulated gene transcription

Publications (2)

Publication Number Publication Date
EP1115733A1 EP1115733A1 (en) 2001-07-18
EP1115733A4 true EP1115733A4 (en) 2003-01-22

Family

ID=26794273

Family Applications (2)

Application Number Title Priority Date Filing Date
EP99945523A Withdrawn EP1115733A4 (en) 1998-08-27 1999-08-27 SEQUENCE CHARACTERISTICS OF THE HYPOXIA-REGULATED GENE TRANSCRIPTION
EP99945522A Withdrawn EP1107797A4 (en) 1998-08-27 1999-08-27 HYPOXIA-REGULATED GENES.

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP99945522A Withdrawn EP1107797A4 (en) 1998-08-27 1999-08-27 HYPOXIA-REGULATED GENES.

Country Status (6)

Country Link
EP (2) EP1115733A4 (enExample)
JP (2) JP2002523072A (enExample)
AU (1) AU5810999A (enExample)
CA (2) CA2341705A1 (enExample)
IL (2) IL141660A0 (enExample)
WO (2) WO2000012525A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4175662B2 (ja) 1996-01-08 2008-11-05 インパルス ダイナミクス エヌ．ヴイ． 電気的筋肉制御装置
US9289618B1 (en) 1996-01-08 2016-03-22 Impulse Dynamics Nv Electrical muscle controller
US9713723B2 (en) 1996-01-11 2017-07-25 Impulse Dynamics Nv Signal delivery through the right ventricular septum
EP1002862A1 (en) * 1998-11-12 2000-05-24 Nitsch, Roger M., Prof. Dr. Methods of diagnosing or treating neurological diseases
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
PL362606A1 (en) * 2000-11-28 2004-11-02 Wyeth Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
EP1795597B1 (en) * 2001-05-31 2010-08-18 Chiba-Prefecture Nucleic acids isolated from a neuroblastoma
US20030068636A1 (en) 2001-06-21 2003-04-10 Millennium Pharmaceuticals, Inc. Compositions, kits and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
CA2503390A1 (en) * 2002-11-01 2004-05-21 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US11439815B2 (en) 2003-03-10 2022-09-13 Impulse Dynamics Nv Protein activity modification
US9931503B2 (en) 2003-03-10 2018-04-03 Impulse Dynamics Nv Protein activity modification
EP1670425A4 (en) * 2003-10-07 2008-04-16 Quark Pharmaceuticals Inc BONE MORPHOGENETIC PROTEIN (BMP) 2A AND ITS APPLICATIONS
WO2006119467A2 (en) 2005-05-04 2006-11-09 Impulse Dynamics Nv Protein activity modification
US11779768B2 (en) 2004-03-10 2023-10-10 Impulse Dynamics Nv Protein activity modification
US8934975B2 (en) 2010-02-01 2015-01-13 Metacure Limited Gastrointestinal electrical therapy
JP2011206049A (ja) * 2010-03-08 2011-10-20 Sumio Sugano 壊死マーカー及びその用途
JP2013220090A (ja) * 2012-04-19 2013-10-28 Tohoku Univ 眼疾患治療に使用する薬剤スクリーニング方法
JP2019535839A (ja) 2016-11-29 2019-12-12 ピュアテック ヘルス エルエルシー 治療剤の送達のためのエクソソーム

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039426A1 (en) * 1995-06-06 1996-12-12 The Johns Hopkins University School Of Medicine Hypoxia inducible factor-1 and method of use
WO1998039448A2 (en) * 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 human secreted proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000353A1 (en) 1991-06-20 1993-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sequences characteristic of human gene transcription product
US5731294A (en) * 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
EP1002862A1 (en) * 1998-11-12 2000-05-24 Nitsch, Roger M., Prof. Dr. Methods of diagnosing or treating neurological diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039426A1 (en) * 1995-06-06 1996-12-12 The Johns Hopkins University School Of Medicine Hypoxia inducible factor-1 and method of use
WO1998039448A2 (en) * 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 human secreted proteins

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BAE M K ET AL: "Identification of genes differentially expressed by hypoxia in hepatocellular carcinoma cells.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. UNITED STATES 4 FEB 1998, vol. 243, no. 1, 4 February 1998 (1998-02-04), pages 158 - 162, XP002210567, ISSN: 0006-291X *
BLANCHER C ET AL: "THE MOLECULAR BASIS OF THE HYPOXIA RESPONSE PATHWAY: TUMOUR HYPOXIA AS A THERAPY TARGET", CANCER METASTASIS, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL, vol. 17, 1998, pages 187 - 194, XP002924629, ISSN: 0167-7659 *
BUDANOV A V; ET AL: "Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability", ONCOGENE, vol. 21, 1 January 2002 (2002-01-01), pages 6017 - 6031, XP003017166 *
See also references of WO0012525A1 *
VELASCO-MIGUEL S. ET AL.: "PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes", ONCOGENE, vol. 18, no. 1, 7 January 1999 (1999-01-07), pages 127 - 137 *
WIEMANN S ET AL: "Toward a catalog of human genes and proteins: sequencing and analysis of 500 novel complete protein coding human cDNAs.", GENOME RESEARCH. UNITED STATES MAR 2001, vol. 11, no. 3, March 2001 (2001-03-01), pages 422 - 435, XP002221682, ISSN: 1088-9051 *

Also Published As

Publication number Publication date
WO2000012139B1 (en) 2000-05-04
JP2002525081A (ja) 2002-08-13
JP2002523072A (ja) 2002-07-30
EP1107797A4 (en) 2002-10-16
WO2000012525A1 (en) 2000-03-09
WO2000012139A1 (en) 2000-03-09
IL141660A0 (en) 2002-03-10
EP1107797A2 (en) 2001-06-20
CA2341705A1 (en) 2000-03-09
EP1115733A1 (en) 2001-07-18
IL141666A0 (en) 2002-03-10
CA2341518A1 (en) 2000-03-09
AU5810999A (en) 2000-03-21

Similar Documents

Publication Publication Date Title
IL141660A0 (en) Sequences characteristic of hypoxia-regulated gene transcription
HUP0103571A3 (en) Characterisation of gene function using double stranded rna inhibition
AU1824101A (en) Nucleotide sequences of moraxella catarrhalis genome
AU1750800A (en) Purified and isolated (piwi) family genes and gene products and methods employing same
IL139735A0 (en) Genes for the biosynthesis of epothilones
AU1488501A (en) Methods of inhibiting metastasis
AU5328600A (en) Nucleotide sequences for gene regulation and methods of use thereof
EP1581614A3 (en) Nucleotide sequences for gene regulation and methods of use thereof
AU3548799A (en) Libraries of expressible gene sequences
AUPQ659800A0 (en) Genetic sequences and uses therefor
AU1082701A (en) Short segments of dap-kinase
AUPP727398A0 (en) Methods of identifying antigen gene sequences
AU2001293741A1 (en) Nucleotide sequences coding for the suga gene
EP1066404A4 (en) METHOD FOR PRODUCING LIBRARIES OF EXPRESSABLE GENE SEQUENCES
AU2002221104A1 (en) Method of detecting relation between genes
AU7461900A (en) Nucleotide sequences
AU2001289807A1 (en) Nucleotide sequences coding for the pstc2 gene
AU2001264845A1 (en) Nucleotide sequences encoding ramosa 1 gene and methods of use for same
AU2001279804A1 (en) Nucleotide sequences coding for the hisc2 gene
AU2001293730A1 (en) Nucleotide sequences which code for the chra gene
IL148798A0 (en) Sequences characteristic of bladder cancer
AU2001293723A1 (en) Nucleotide sequences coding for the dep33 gene
AU2001279809A1 (en) Nucleotide sequences coding for the thya gene
AU1123501A (en) Methylation of unstable sequences
GB9814536D0 (en) Characterisation of gene function using double stranded rna inhibition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010326

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: QUARK BIOTECH, INC.

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07H 21/00 A, 7C 07K 14/435 B, 7C 07K 14/47 B

A4 Supplementary search report drawn up and despatched

Effective date: 20021209

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20070131

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: QUARK PHARMACEUTICALS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110301